Editas Medicine submits IND application for EDIT-301

 

• Editas Medicine (NASDAQ:EDIT) has submitted an Investigational New Drug (IND) application with the FDA for the initiation of a Phase 1/2 clinical trial of EDIT-301, an experimental CRISPR/Cas12a gene editing medicine in development for the treatment of sickle cell disease.
• The Company previously received Rare Pediatric Disease designation from the FDA for EDIT-301.
• Sickle cell disease is caused by a mutation in the beta-globin gene that leads to polymerization of the sickle hemoglobin protein
• https://seekingalpha.com/news/3643158-editas-medicine-submits-ind-application-for-editminus-301